NEW YORK, Jan. 11, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Ophthotech Corporation (“Ophthotech”) (NASDAQ:OPHT) between May 11, 2015 and December 12, 2016. You are hereby notified that Levi & Korsinsky has commenced the class action Micholle v. Ophthotech Corporation, et al. (Case No. 1:17-cv-00210) in the USDC for the Southern District of New York. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, Ophthotech made overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone. The complaint further alleges that these statements caused Ophthotech stock to trade at artificially inflated prices.
On December 12, 2016, Ophthotech announced that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statically significant improvement over patients only receiving Lucentis. Following this news, shares of Ophthotech fell approximately 86% to close at $5.29.
Take Action: if you suffered a loss in Ophthotech you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Apple Turns 50: From Garage Startup to AI Crossroads
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Britain Courts Anthropic Amid US Defense Department Dispute
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 



